← Leaderboards
Saar Gill
University Of Pennsylvania
$5,197,347
Attributed
$6,432,457
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2015–25$2.5M$1.9M$1.3M$625K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,432,457 · 6
By mechanism
P01$3,123,076 · 3
R01$2,070,482 · 1
K08$839,160 · 1
R41$399,739 · 1
Top collaborators
- Frederick Bennett3 shared
- Jeremy A Elser1 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- George M Shaw$56,045,759
- Mirko Paiardini$32,628,549
- Katharine June Bar$15,418,177
- Michael R Betts$25,350,826
- Dennis Larry Kolson$16,900,832
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsCell TherapyChimeric Antigen ReceptorImmunotherapyHematologic NeoplasmsAntigensMalignant NeoplasmsCd19 GeneGenetic EngineeringEngineeringB Lymphoid MalignancyIn VivoAllogenicT-LymphocyteT Cell TherapyChemotherapyLeukemiaMissionResponseClinical TrialsDesignHematopoietic Stem CellsPhysiciansScientist
Grant awards (17)
Base editing approaches to enable an HIV cure$691,427
P01 · FY2025 · AI · contact PI
Amyloid Beta CAR Macrophages: a cell engineering strategy to clear pathogenic proteins$644,077
R01 · FY2025 · NS · contact PI
Next-generation genetic engineering of the pan-leukocyte antigen CD45 to facilitate CAR-T cell therapy against hematologic malignancies$525,419
P01 · FY2025 · CA · contact PI
Preclinical development of a tandem CART / HSC transplantation platform for hematologic malignancies$399,739
R41 · FY2025 · CA
Amyloid Beta CAR Macrophages: a cell engineering strategy to clear pathogenic proteins$715,640
R01 · FY2024 · NS · contact PI
Next-generation genetic engineering of the pan-leukocyte antigen CD45 to facilitate CAR-T cell therapy against hematologic malignancies$561,800
P01 · FY2024 · CA · contact PI
Amyloid Beta CAR Macrophages: a cell engineering strategy to clear pathogenic proteins$710,765
R01 · FY2023 · NS · contact PI
Next-generation genetic engineering of the pan-leukocyte antigen CD45 to facilitate CAR-T cell therapy against hematologic malignancies$472,594
P01 · FY2023 · CA · contact PI
Project 2: Towards a safe and effective AML treatment strategy using anti-CD33 CAR T cells in combination with CAR-resistant hematopoietic stem cells$300,287
P01 · FY2019 · CA · contact PI
Chimeric Antigen Receptor T cell Therapy for Acute Myeloid Leukemia (AML)$167,832
K08 · FY2019 · CA · contact PI
Project 2: Towards a safe and effective AML treatment strategy using anti-CD33 CAR T cells in combination with CAR-resistant hematopoietic stem cells$15,408
P01 · FY2019 · CA · contact PI
Project 2: Towards a safe and effective AML treatment strategy using anti-CD33 CAR T cells in combination with CAR-resistant hematopoietic stem cells$289,910
P01 · FY2018 · CA · contact PI
Chimeric Antigen Receptor T cell Therapy for Acute Myeloid Leukemia (AML)$167,832
K08 · FY2018 · CA · contact PI
Project 2: Towards a safe and effective AML treatment strategy using anti-CD33 CAR T cells in combination with CAR-resistant hematopoietic stem cells$266,231
P01 · FY2017 · CA · contact PI
Chimeric Antigen Receptor T cell Therapy for Acute Myeloid Leukemia (AML)$167,832
K08 · FY2017 · CA · contact PI
Chimeric Antigen Receptor T cell Therapy for Acute Myeloid Leukemia (AML)$167,832
K08 · FY2016 · CA · contact PI
Chimeric Antigen Receptor T cell Therapy for Acute Myeloid Leukemia (AML)$167,832
K08 · FY2015 · CA · contact PI